Allergy最新文献

{"title":"Algorithms in allergy: Management of allergic reactions to COVID-19 vaccines.","authors":"Mary Johnson, Olivia Kline, Maria Jose Torres Jaen, Kari C Nadeau","doi":"10.1111/all.16358","DOIUrl":"https://doi.org/10.1111/all.16358","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maximizing safety of ultrasound-guided intralymphatic allergen administration in the superficial inguinal lymph node.","authors":"Min-Jeong Cho, Victoria Nguyen, Hiroo Suami, Casey T Kraft, Monica T Kraft","doi":"10.1111/all.16379","DOIUrl":"https://doi.org/10.1111/all.16379","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142542262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergy discordant twins do not exhibit differences in gene expression in non-switched and switched B cells.","authors":"Stephan Schneider, Pattraporn Satitsuksanoa, Huseyn Babayev, Willem van de Veen, Iris Chang, Minglin Yang, Cezmi A Akdis, Kari Nadeau, Mübeccel Akdis","doi":"10.1111/all.16376","DOIUrl":"https://doi.org/10.1111/all.16376","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days","authors":"Josje Janna Otten, Rik Johannes Leonardus van der Lans, Hester Beatrice Emilie Elzinga, Gwijde Flavius Jacobus Petrus Maria Adriaensen, Linda Berendina Laurentia Benoist, Rienk D. Hoven, Sven Seys, Wytske Johanna Fokkens, Sietze Reitsma","doi":"10.1111/all.16357","DOIUrl":"10.1111/all.16357","url":null,"abstract":"<p>Olfactory dysfunction is one of the main complaints of patients suffering from Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), significantly affecting their quality of life. In real-life studies, dupilumab effectively enhances olfactory function within 6 months of treatment.<span><sup>1, 2</sup></span> However, the speed and efficacy of this effect on olfactory function during the initial weeks of treatment has to be determined.</p><p>The data were reported in this letter stem from a prospective observational cohort (PolyREG).<span><sup>2</sup></span> Patients from this cohort were treated with dupilumab subcutaneously (300 mg 1×/2 weeks) for CRSwNP. Patients were asked to use the Galenus Health App reporting Visual Analogue Scale (VAS) scores of their complaints in their Health Diary.<span><sup>3</sup></span> With special regard to loss of smell, the question ‘How much does smell loss bother you today?’ was answered with a VAS score (0–10 cm; 0 being not bothersome at all, 10 being the most bothersome) with a cut-off of >5.2 for olfactory dysfunction.<span><sup>4</sup></span> In total, 72 patients filled out a VAS score on olfactory dysfunction at baseline and at least another day during the first 28 days of dupilumab treatment. Also, the outcomes of the Sniffin' Sticks-12 Identification Test (SSIT-12) were collected at baseline and after 28 days of treatment.</p><p>Baseline demographics of these patients are shown as repository data (Table S1). Figure 1 shows the outcomes of baseline and follow-up SSIT-12 and VAS measurements (other outcomes are listed in Table S2). At baseline, the median SSIT-12 score was 3 (IQR 2–4) indicating anosmia (Figure 1B). After 28 days, the median SSIT-12 score increased to 6 (IQR 3–9), Wilcoxon signed-rank test: <i>p</i> < .001, with 50% of the patients having hyposmia or normosmia (Figure 1B). Similarly, 93.7% of patients reported a VAS score on the loss of smell of >5.2 at baseline, indicating olfactory dysfunction. Over the subsequent 28 days of treatment, this percentage significantly declined to 44.2% (Figure 1: Pearson <i>r</i> = .924, <i>p</i> < .001). The mean VAS score in the first week of treatment significantly predicted the outcome of the SSIT-12 after 4 weeks of treatment (linear regression <i>F</i><sub>(1,97)</sub> = 6.7, <i>p</i> = .01). As such, the data show a rapid olfactory function improvement in more than half of the patients treated with dupilumab, starting after 1–2 injections.</p><p>Lastly, a retrospective analysis of these 72 patients' medical records was conducted to see if olfactory function improvement was previously reported by the patient during a course of oral corticosteroids (OCS) prior to initiation of dupilumab treatment.<span><sup>5</sup></span> Data was available for 63 of 72 patients, thus giving an OCS-responsive (<i>n</i> = 51) (OCS-R) or OCS-unresponsive (<i>n</i> = 12) (OCS-U) group. The amount of previous sinus surgeries did not statistically differ betwe","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 11","pages":"3166-3168"},"PeriodicalIF":12.6,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16357","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pesticides as an overlooked exposomic association in allergic asthma exacerbations: A nationwide database study","authors":"Joana Vitte, Leila Bouazzi, Coralie Barbe, Bach-Nga Pham, Stéphane Sanchez","doi":"10.1111/all.16380","DOIUrl":"10.1111/all.16380","url":null,"abstract":"<p>Occupational pesticide exposure (PE) is a causal factor for asthma, but there is only low certainty of evidence for non-occupational PE, considered a minor exposomic risk.<span><sup>1-3</sup></span> Pesticides share the One Health pathophysiology of exposome-related diseases: leaky barrier due to epithelial lesions and inflammation driven by epithelium-derived alarmins. Leaky barriers allow further penetration of noxious molecules while the vicious circle of chronic inflammation, most often type 2-skewed, fosters and exacerbates adaptive allergic responses to common airborne allergens.<span><sup>3-5</sup></span> Direct toxicity, allergenicity, and epigenetic effects have also been described.<span><sup>4, 6-9</sup></span> Thus, the association between PE and asthma can be assessed as “incidence” (asthma development in exposed populations) or as “impact on asthma outcomes” (exacerbation, lung function deterioration etc).<span><sup>1, 2</sup></span> Our study belongs to the second category. The lack of general population cohorts addressing the relationship between PE and asthma outcomes prompted us to build a nationwide dataset (F20210106180024/2203674v, French healthcare data studies registry) using four French databases (Figure 1; Supporting Methods—Data S1). Institutional Review Board approval was waived for this retrospective observational study with anonymized data.</p><p>Cases (<i>n</i> = 21,050) were defined as 2014–2020 stays with an ICD-10 primary diagnosis of allergic or mixed asthma (J45.0, J45.8). Controls (<i>n</i> = 8782) were defined as stays with a primary diagnosis of non-allergic asthma (J45.1) during the same period (Figure S1). Cases were matched 1:1 with controls on age, sex, comorbidities, month and year of the hospital stay (Supporting Methods—Data S1). Patients' residence place was encoded from ZIP code (Table S1). PE was estimated as the index of non-occupational annual pesticide purchases per ZIP code area. Matched (<i>n</i> = 12,716) cases and controls were compared according to exposomic variables: PE, lifestyle, and socio-economic indicators (Figure 1; Table S2). The comparison between the two groups: cases (allergic and mixed asthma) and controls (non-allergic asthma) is presented using odds-ratio (OR) to estimate the association between exposure and outcome.</p><p>Univariate analysis revealed higher exposure to any pesticide in cases: 7.81 ± 18.6 kg/ha mean ± SD in cases versus 6.50 ± 18.1 kg/ha in controls, OR 1.07, <i>p</i> < .001 (Table 1). The association was significant for each subgroup of pesticides, with higher exposure in cases than in controls: insecticides (OR 1.09, <i>p</i> = .007), fungicides (OR 2.45, <i>p</i> = .002) and herbicides (OR 1.84, <i>p</i> = .002).</p><p>In multivariate analysis, after adjustment on age, sex, and comorbidities (Table 1), and on social deprivation (Table S3), significantly higher exposure persisted in cases compared to controls for any pesticide (OR = 1.06, <i>p</i> = .00","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 12","pages":"3505-3508"},"PeriodicalIF":12.6,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16380","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: A randomized, double-blind controlled explorer trial.","authors":"Xiaochun Liu, Yang Luo, Xingyu Chen, Mingyang Wu, Xiaoqiang Xu, Jingru Tian, Yingxia Gao, Jun Zhu, Zhifeng Wang, Yuan Zhou, Yu Zhang, Xiaokai Wang, Wei Li, Qianjin Lu, Xu Yao","doi":"10.1111/all.16372","DOIUrl":"https://doi.org/10.1111/all.16372","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is a novel treatment for inflammatory diseases. Herein, we assess its safety, efficacy, and immunological impact in patients with moderate-to-severe atopic dermatitis (AD).</p><p><strong>Methods: </strong>In this randomized, double-blind, placebo-controlled clinical trial, we performed the efficacy and safety assessment of FMT for moderate-to-severe adult patients with AD. All patients received FMT or placebo once a week for 3 weeks, in addition to their standard background treatments. Patients underwent disease severity assessments at weeks 0, 1, 2, 4, 8, 12, and 16, and blood and fecal samples were collected for immunologic analysis and metagenomic shotgun sequencing, respectively. Safety was monitored throughout the trial.</p><p><strong>Results: </strong>Improvements in eczema area and severity index (EASI) scores and percentage of patients achieving EASI 50 (50% reduction in EASI score) were greater in patients treated with FMT than in placebo-treated patients. No serious adverse reactions occurred during the trial. FMT treatment decreased the Th2 and Th17 cell proportions among the peripheral blood mononuclear cells, and the levels of TNF-α, and total IgE in serum. By contrast, the expression levels of IL-12p70 and perforin on NK cells were increased. Moreover, FMT altered the abundance of species and functional pathways of the gut microbiota in the patients, especially the abundance of Megamonas funiformis and the pathway for 1,4-dihydroxy-6-naphthoate biosynthesis II.</p><p><strong>Conclusion: </strong>FMT was a safe and effective therapy in moderate-to-severe adult patients with AD; the treatment changed the gut microbiota compositions and functions.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STING-dependent induction of neutrophilic asthma exacerbation in response to house dust mite.","authors":"Yasmine Messaoud-Nacer, Elodie Culerier, Stéphanie Rose, Isabelle Maillet, Rania Boussad, Chloé Veront, Florence Savigny, Bernard Malissen, Urszula Radzikowska, Milena Sokolowska, Gabriel V L da Silva, Michael R Edwards, David J Jackson, Sebastian L Johnston, Bernhard Ryffel, Valerie F Quesniaux, Dieudonnée Togbe","doi":"10.1111/all.16369","DOIUrl":"https://doi.org/10.1111/all.16369","url":null,"abstract":"<p><strong>Background: </strong>Severe refractory, neutrophilic asthma remains an unsolved clinical problem. STING agonists induce a neutrophilic response in the airways, suggesting that STING activation may contribute to the triggering of neutrophilic exacerbations. We aim to determine whether STING-induced neutrophilic lung inflammation mimics severe asthma.</p><p><strong>Methods: </strong>We developed new models of neutrophilic lung inflammation induced by house dust mite (HDM) plus STING agonists diamidobenzimidazole (diABZI) or cGAMP in wild-type, and conditional-STING-deficient mice. We measured DNA damage, cell death, NETs, cGAS/STING pathway activation by immunoblots, N1/N2 balance by flow cytometry, lung function by plethysmography, and Th1/Th2 cytokines by multiplex. We evaluated diABZI effects on human airway epithelial cells from healthy or patients with asthma, and validated the results by transcriptomic analyses of rhinovirus infected healthy controls vs patients with asthma.</p><p><strong>Results: </strong>DiABZI administration during HDM challenge increased airway hyperresponsiveness, neutrophil recruitment with prominent NOS2⁺ARG1^- type 1 neutrophils, protein extravasation, cell death by PANoptosis, NETs formation, extracellular dsDNA release, DNA sensors activation, IFNγ, IL-6 and CXCL10 release. Functionally, STING agonists exacerbated airway hyperresponsiveness. DiABZI caused DNA and epithelial barrier damage, STING pathway activation in human airway epithelial cells exposed to HDM, in line with DNA-sensing and PANoptosis pathways upregulation and tight-junction downregulation induced by rhinovirus challenge in patients with asthma.</p><p><strong>Conclusions: </strong>Our study identifies that triggering STING in the context of asthma induces cell death by PANoptosis, fueling the flame of inflammation through a mixed Th1/Th2 immune response recapitulating the features of severe asthma with a prognostic signature of type 1 neutrophils.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142520358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From bite to brain: Neuro-immune interactions in food allergy","authors":"Vikki Houghton,&nbsp;Thomas Eiwegger,&nbsp;Esther Borges Florsheim,&nbsp;Rebecca C. Knibb,&nbsp;Sandrine Thuret,&nbsp;Alexandra F. Santos","doi":"10.1111/all.16366","DOIUrl":"10.1111/all.16366","url":null,"abstract":"<p>Immunoglobulin E (IgE)-mediated food allergies are reported to affect around 3.5% of children and 2.4% of adults, with symptoms varying in range and severity. While being the gold standard for diagnosis, oral food challenges are burdensome, and diagnostic tools based on specific IgE can be flawed. Furthering our understanding of the mechanisms behind food allergy onset, severity and persistence could help reveal immune profiles associated with the disease, to ultimately aid in diagnosis. Alterations to cytokine levels and immune cell ratios have been identified, though further research is needed to fully capture the heterogenous nature of food allergy. Moreover, the existence of such immune alterations also raises the question of potential wider systemic effects. For example, recent research has emphasised the existence and impact of neuro-immune interactions and implicated behavioural and neurological changes associated with food allergy. This review will provide an overview of such food allergy-driven neuro-immune interactions, with the aim of emphasising the importance of furthering our understanding of the immune mechanisms underlying IgE-mediated food allergy.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"79 12","pages":"3326-3340"},"PeriodicalIF":12.6,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16366","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blocking the HIF‐1α/glycolysis axis inhibits allergic airway inflammation by reducing ILC2 metabolism and function","authors":"Xiaogang Zhang, Jingping Liu, Xinyao Li, Guilang Zheng, Tianci Wang, Hengbiao Sun, Zhengcong Huang, Junyu He, Ju Qiu, Zhibin Zhao, Yuxiong Guo, Yumei He","doi":"10.1111/all.16361","DOIUrl":"https://doi.org/10.1111/all.16361","url":null,"abstract":"BackgroundThe role of lung group 2 innate lymphoid cell (ILC2) activation in allergic asthma is increasingly established. However, the regulatory mechanisms underlying hypoxia‐inducible factor‐1α (HIF‐1α)‐mediated glycolysis in ILC2‐mediated allergic airway inflammation remain unclear.ObjectiveTo investigate the role of the HIF‐1α/glycolysis axis in ILC2‐mediated allergic airway inflammation.MethodsGlycolysis and HIF‐1α inhibitors were used to identify their effect on the function and glucose metabolism of mouse and human ILC2s in vivo and vitro. Blocking glycolysis and HIF‐1α in mice under interleukin‐33 (IL‐33) stimulation were performed to test ILC2 responses. Conditional HIF‐1α‐deficient mice were used to confirm the specific role of HIF‐1α in ILC2‐driven airway inflammation models. Transcriptomic, metabolic, and chromatin immunoprecipitation analyses were performed to elucidate the underlying mechanism.ResultsHIF‐1α is involved in ILC2 metabolism and is crucial in allergic airway inflammation. Single‐cell sequencing data analysis and qPCR confirmation revealed a significant upregulation of glycolysis‐related genes, particularly HIF‐1α, in murine lung ILC2s after IL‐33 intranasal administration or injection. Treatment with the glycolysis inhibitor 2‐deoxy‐D‐glucose (2‐DG) and the HIF‐1α inhibitor 2‐methoxyestradiol (2‐ME) abrogated inflammation by suppressing ILC2s function. Conditional HIF‐1α‐deficient mice showed reduced ILC2 response and airway inflammation induced upon IL‐33 or house dust mite (HDM) stimulation. Transcriptome and metabolic analyses revealed significantly impaired glycolysis in lung ILC2s in conditional HIF‐1α knockout mice compared to that in their littermate controls. Chromatin immunoprecipitation results confirmed the transcriptional downregulation of glycolysis‐related genes in HIF‐1α‐knockout and 2‐DG‐treated mice. Furthermore, impaired HIF‐1α/glycolysis axis activation is correlated with downregulated ILC2 in patients with asthma.ConclusionThe HIF‐1α/glycolysis axis is critical for controlling ILC2 responses in allergic airway inflammation and has potential immunotherapeutic value in asthma.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"110 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progranulin derivative attenuates lung neutrophilic infiltration from diesel exhaust particle exposure","authors":"A. Ryang Lee, Mini Jeong, Kyomoon Koo, Sin‐Jeong Kim, Min Ju Pyo, Yeeun Hong, Yura Ha, Keun‐Ai Moon, Hyun Jae Shim, Ji‐Hyang Lee, Hyouk‐Soo Kwon, You Sook Cho","doi":"10.1111/all.16362","DOIUrl":"https://doi.org/10.1111/all.16362","url":null,"abstract":"BackgroundAir pollutants, such as diesel exhaust particles (DEPs), induce respiratory disease exacerbation with neutrophilic infiltration. Progranulin (PGRN), an epithelial cell and macrophage‐derived secretory protein, is associated with neutrophilic inflammation. PGRN is digested into various derivatives at inflammatory sites and is involved in several inflammatory processes. PGRN and its derivatives likely regulate responses to DEP exposure in allergic airway inflammation.AimTo investigate the role of PGRN and its derivatives in the regulation of responses to DEP exposure in allergic airway inflammation.MethodsA murine model of allergic airway inflammation was generated in PGRN‐deficient mice, and they were simultaneously exposed to DEP followed by intranasal administration of full‐length recombinant PGRN (PGRN‐FL) and a PGRN‐derived fragment (FBAC). Inflammatory status was evaluated by bronchoalveolar lavage fluid and histopathologic analyses. Human bronchial epithelial cells were stimulated with DEPs and house dust mites (HDMs), and the effect of FBAC treatment was evaluated by assessing various intracellular signaling molecules, autophagy markers, inflammatory cytokines, and intracellular oxidative stress.ResultsDEP exposure exaggerated neutrophilic inflammation, enhanced IL‐6 and CXCL15 secretions, and increased oxidative stress in the murine model; this effect was greater in PGRN‐deficient mice than in wild‐type mice. The DEP‐exposed mice with PGRN‐FL treatment revealed no change in neutrophil infiltration and higher oxidative stress status in the lungs. On the contrary, FBAC administration inhibited neutrophilic infiltration and reduced oxidative stress. In human bronchial epithelial cells, DEP and HDM exposure increased intracellular oxidative stress and IL‐6 and IL‐8 secretion. Decreased nuclear factor erythroid 2‐related factor 2 (Nrf2) expression and increased phosphor‐p62 and LC3B expression were also observed. FBAC treatment attenuated oxidative stress from DEP and HDM exposure.ConclusionsFBAC reduced neutrophilic inflammation exaggerated by DEP exposure in a mouse model of allergic airway inflammation by reducing oxidative stress. PGRN and PGRN‐derived proteins may be novel therapeutic agents in attenuating asthma exacerbation induced by air pollutant exposure.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"61 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}